PHIO · Phio Pharmaceuticals Corp. · Documents
$0.89
+0.02 (+2.67%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 6, 2026
The latest filing states the doubt was alleviated.
“The Company has limited cash resources, has incurred recurring operating losses and negative cash flows from its operations since its inception and has not yet recognized any product revenues. These factors have previously raised doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 6, 2026
Market Cap
$10.09M
Shares
11.62M
Volume · Oct 20
60.58K
Avg daily vol (3M)
140.97K
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 8-K | Phio Pharmaceuticals completed its first commercial-scale cGMP batch of PH-762 drug substance on October 13, 2026, supporting planned Phase 2b clinical trial initiation in the first quarter of 2027. | 2026-10-13 | — | |
| 8-K | — | 2026-09-28 | — | |
| 8-K | — | 2026-09-14 | — | |
| Investor Event Transcript | — | 2026-09-11 | 2026-09-30 | |
| DEF 14A | — | 2026-08-14 | 2026-09-28 | |
| ARS | — | 2026-08-14 | 2025-12-31 | |
| DEFA14A | — | 2026-08-14 | — | |
| 10-Q | — | 2026-08-06 | 2026-06-30 | |
| 8-K | — | 2026-08-06 | — | |
| 8-K | — | 2026-07-21 | — | |
| 8-K | — | 2026-05-07 | — | |
| 10-Q | — | 2026-05-07 | 2026-03-31 | |
| Investor Event Transcript | — | 2026-04-14 | 2026-06-30 | |
| Investor Event Transcript | — | 2026-04-14 | 2026-06-30 | |
| 8-K | — | 2026-04-08 | — | |
| 8-K | — | 2026-03-30 | — | |
| 10-K | — | 2026-03-05 | 2025-12-31 | |
| 8-K | — | 2026-03-05 | — | |
| 8-K | — | 2026-02-18 | 2026-02-17 | |
| 8-K | — | 2026-02-10 | — | |
| 8-K | — | 2026-01-20 | — | |
| 8-K | — | 2025-12-23 | — | |
| 8-K | — | 2025-11-25 | — | |
| S-3 | — | 2025-11-20 | — | |
| 8-K | — | 2025-11-13 | — | |
| 10-Q | — | 2025-11-13 | 2025-09-30 | |
| 8-K | — | 2025-11-06 | 2025-11-03 | |
| 8-K | — | 2025-11-03 | — | |
| 8-K | — | 2025-10-31 | — | |
| 8-K | — | 2025-09-15 | 2025-09-11 | |
| 8-K | — | 2025-09-03 | — | |
| DEFA14A | — | 2025-08-28 | — | |
| S-3 | — | 2025-08-15 | — | |
| 10-Q | — | 2025-08-14 | 2025-06-30 | |
| 8-K | — | 2025-08-14 | — | |
| DEF 14A | — | 2025-07-30 | 2025-09-11 | |
| 8-K | — | 2025-07-30 | 2025-07-25 | |
| ARS | — | 2025-07-30 | 2024-12-31 | |
| DEFA14A | — | 2025-07-30 | — | |
| 8-K | — | 2025-07-25 | — | |
| 8-K | — | 2025-07-07 | — | |
| 8-K | — | 2025-06-26 | 2025-06-25 | |
| 8-K | — | 2025-06-12 | 2025-06-06 | |
| 8-K | — | 2025-05-15 | — | |
| 10-Q | — | 2025-05-15 | 2025-03-31 | |
| 8-K | — | 2025-05-07 | — | |
| 8-K | — | 2025-04-22 | 2025-04-17 | |
| 8-K | — | 2025-04-09 | — | |
| 8-K | — | 2025-03-31 | — | |
| 10-K | — | 2025-03-31 | 2024-12-31 |
Showing 1–50 of 174 filings